Suven to participate in 11th clinical trials on Alzheimer's disease in Spain

23 Oct 2018 Evaluate

Suven Life Sciences is participating and presenting the baseline patient demographics and scales from the ongoing phase-2a proof-of-concept trial of SUVN-502 for moderate Alzheimer’s Disease at 11th clinical trials on Alzheimer's disease (CTAD) during October 24-27, 2018 at Barcelona, Spain.

SUVN-502 is a promising pure, 5-HT6 receptor antagonist in development for the treatment of moderate Alzheimer’s disease, a novel triple combination treatment approach. This trial evaluates the efficacy and safety of SUVN-502 added to background stable donepezil and memantine, a triple therapy in subjects with moderate AD dementia.

At CTAD, Suven is presenting the baseline patient demographics and scales from the ongoing phase-2a proof-of-concept trial of SUVN-502 for moderate Alzheimer’s disease. Top-line efficacy results from this study are expected during August/September of 2019

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.

Suven Life Sciences Share Price

133.50 -3.40 (-2.48%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×